(Reuters) - Moderna Inc confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning of March, as long as it succeeds in gaining local regulatory approval.
The company’s statement did not disclose other terms of the agreement, including the number of doses it agreed to supply.
U.K. Health Minister Matt Hancock told a news conference on Monday that the deal would see the U.S. startup, one of two vaccine makers who have so far published positive data on final-stage trials, supply five million doses from next spring.
Moderna on Monday said mRNA-1273 was 94.5% effective in preventing COVID-19 based on interim data from its late-stage clinical trial.
Read more from the original article:
风险提示：本文所述仅代表作者个人观点，不代表 Followme 的官方立场。Followme 不对内容的准确性、完整性或可靠性作出任何保证，对于基于该内容所采取的任何行为，不承担任何责任，除非另有书面明确说明。
暂无评论，立马抢沙发